ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.
Wang YH, Lin CC, Lee SH, Tsai CH, Wu SJ, Hou HA, Huang TC, Kuo YY, Yao M, Chang K, Lin CW, Lin YC, Tien FM, Chou WC, Tang JL, Tien HF.
Wang YH, et al. Among authors: lin cw, lin cc, lin yc.
Blood Cancer J. 2020 Oct 12;10(10):99. doi: 10.1038/s41408-020-00364-5.
Blood Cancer J. 2020.
PMID: 33046688
Free PMC article.
Clinical Trial.
No abstract available.